Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

Siegal, Deborah M., Curnutte, John T., Connolly, Stuart J., Lu, Genmin, Conley, Pamela B., Wiens, Brian L., Mathur, Vandana S., Castillo, Janice, Bronson, Michele D., Leeds, Janet M., Mar, Florie A., Gold, Alex, Crowther, Mark A.·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1510991

Cited by (1,000)

Items 301–400 of 1,000

Venous thromboembolism in Latin America: a review and guide to diagnosis and treatment for primary care
Jose Manuel Ceresetto · 2016 · Clinics
Management of antithrombotic therapy during cardiac implantable device surgery
Ahmed AlTurki, Riccardo Proietti, David H. Birnie, Vidal Essebag · 2016 · Journal of Arrhythmia
Surfing the Blood Coagulation Cascade: Insight into the Vital Factor Xa
Nicolás Núñez-Navarro, Fabian Mauricio Santana-Romo, Loreto P. Parra, Flavia C. M. Zacconi · 2018 · Current Medicinal Chemistry
Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options
Jack Ansell · 2016 · American Journal of Cardiovascular Drugs
Reversal agents for use with direct and indirect anticoagulants
Maureen A. Smythe, Toby C. Trujillo, John R. Fanikos · 2016 · American Journal of Health-System Pharmacy
Use of novel oral anticoagulant agents in venous thromboembolism
Shivanshu Madan, Shenil Shah, Patrick Dale, Sasan Partovi, Sahil A. Parikh · 2016 · Cardiovascular Diagnosis and Therapy
Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis
Charles Michael White, Kimberly Snow Caroti, Youssef Bessada, Adrián Vladimir Hernández, William L. Baker, Paul P. Dobesh, Heleen van Haalen, Kirsty M. Rhodes, Craig Ian Coleman · 2024 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Anti-Xa activity in apixaban overdose: a case report
James Barton, Anselm Wong, Andis Graudins · 2016 · Clinical Toxicology
Venous thromboembolism — recommendations on the prevention, diagnostic approach and management. The 2017 Polish Consensus Statement
Witold Zbyszek Tomkowski, Paweł Kuca, Tomasz Urbanek, Dariusz Chmielewski, Zbigniew Krasiński, Piotr Pruszczyk, Jerzy Windyga, Grzegorz Oszkinis, Arkadiusz Jawień, Janusz Burakowski et al. · 2017 · Acta Angiologica
Stroke prevention in atrial fibrillation: State of the art
Yan‐Guang Li, Gregory Y.H. Lip · 2018 · International Journal of Cardiology
Bleeding in anticoagulated patients with atrial fibrillation: practical considerations
Anetta Undas, Leszek Drabik, Tatjana Potpara · 2020 · Kardiologia Polska
EURASIAN CLINICAL RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION
Golitsyn Sp, Е. П. Панченко, Кропачева Екатерина Станиславовна, Lada Iu. Laiovich, E. B. Maykov, Nikolay Yu. Mironov, Olga O. Shakhmatova · 2019 · Eurasian heart journal
Anticoagulation Reversal
Erica Simon, Matthew Jay Streitz, Daniel J. Sessions, Colin G. Kaide · 2018 · Emergency Medicine Clinics of North America
Emergent Bleeding in Patients Receiving Direct Oral Anticoagulants
Richard L. Summers, Sarah A. Sterling · 2016 · Air Medical Journal
Direct oral anticoagulants: unique properties and practical approaches to management
Geoffrey D. Barnes, Brian Kurtz · 2016 · Heart
New Oral Anticoagulants and Their Reversal Agents
Andrea Morotti, Joshua Norkin Goldstein · 2016 · Current Treatment Options in Neurology
Management of anticoagulation with rivaroxaban in trauma and acute care surgery
Sara P. Myers, Esmaeel Reza Dadashzadeh, Jessica Ho Yan Cheung, Louis H. Alarcon, Matthew Kutcher, Joshua B. Brown, Matthew D. Neal · 2016 · The Journal of Trauma: Injury, Infection, and Critical Care
Recent Advances in the Acute Management of Intracerebral Hemorrhage
Joseph D. Burns, Jennifer L. Fisher, Anna Marisa Cervantes-Arslanian · 2018 · Neurosurgery Clinics of North America
How I manage patients with anticoagulation-associated bleeding or urgent surgery
Thomas C. Sauter, Balthasar Eberle, Walter Alfred Wuillemin, Thomas Thiele, Anne Angelillo‐Scherrer, Aristomenis Konstantinos Exadaktylos, Gabor Erdoes, Adam C. Cuker, Michael Nagler · 2018 · Swiss Medical Weekly
Direct oral anticoagulants use in elderly patients with non valvular atrial fibrillation: state of evidence
Giulia Benedetti, Matteo Neccia, Luciano Agati · 2018 · Minerva Cardiology and Angiology
Overview and Practical Application of Coagulation Assays in Managing Anticoagulation with Direct Oral Anticoagulants (DOACs)
Jessica Rimsans, Jonathan Douxfils, Maureen A. Smythe, Robert C. Gosselin · 2020 · Current Pharmacology Reports
Managing high blood pressure during acute ischemic stroke and intracerebral hemorrhage
Karen Appiah, Jatinder Singh Minhas, Thompson Gordon Robinson · 2017 · Current Opinion in Neurology
Heparin Insensitivity and Thrombotic Risk Associated With Sequential Uses of Prothrombin Complex Concentrate and Andexanet Alfa for Apixaban Reversal During Acute Type A Aortic Dissection Repair: A Case Report
Brian Brenner, Jessica Guerra, Campbell Williams, Keith E. Littlewood, John A. Kern, Kenichi A. Tanaka, John S. McNeil, Venkat Reddy Mangunta · 2022 · A&A Practice
Clinical standards for patient blood management and perioperative hemostasis and coagulation management. Position Paper of the Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI)
Gilda Cinnella, Marco Pavesi, Andrea DE GASPERI, Marco Ranucci, Lucia Mirabella · 2019 · Minerva Anestesiologica
Update and Review of Bleeding Considerations in Dermatologic Surgery: Anticoagulants and Antiplatelets
Sanjana Iyengar, Danielle Yeager, Joel L. Cohen, David Ozog · 2019 · Dermatologic Surgery
Four-Factor Prothrombin Complex Concentrate for the Reversal of Direct Oral Anticoagulants
Ilanit Zada, Shan Wang, Meredith B. Akerman, Adel F. Hanna · 2019 · Journal of Intensive Care Medicine
The AAST prospective observational multicenter study of the initial experience with reversal of direct oral anticoagulants in trauma patients
Brent J. Emigh, Leslie M. Kobayashi, Miroslav Kopp, Mitch Daley, Lindsey N. Teal, James M. Haan, Clay Cothren Burlew, Raminder Nirula, Forrest O. Moore, Sigrid Katharine Burruss et al. · 2021 · The American Journal of Surgery
Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro® Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients
Daniel Oberladstätter, Christoph J. Schlimp, Johannes Zipperle, Marcin Filip Osuchowski, Wolfgang Voelckel, Oliver Grottke, Herbert Schöchl · 2021 · Journal of Clinical Medicine
Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US
John R. Fanikos, Joshua Norkin Goldstein, Belinda Lovelace, Anne C. Beaubrun, Robert S. Blissett, Filipa Aragão · 2022 · Journal of Medical Economics
Diretriz Brasileira de Fibrilação Atrial – 2025
Fátima Dumas Cintra, Cristiano Faria Pisani, André Gustavo da Silva Rezende, Benhur Davi Henz, Luciana Armaganijan, Maurício Pimentel, Renato D. Lópes, Thais Aguiar do Nascimento, Adalberto M. Lorga-Filho, Afonso de Albuquerque et al. · 2025 · Arquivos Brasileiros de Cardiologia
Report of the American Heart Association (AHA) Scientific Sessions 2015, Orlando
Yoshiyasu Aizawa, Mai Kimura, Takashi Kohno, Jun Fujita, Keiichi Fukuda · 2015 · Circulation Journal
Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal
Özgür Karcıoğlu, Sehmus Zengin, Bilgen Özkaya, Eylem Ersan, Sarper Yılmaz, Göksu Afacan, Derya Abuşka, Mandana Hosseinzadeh, Selman Yeniocak · 2021 · Cardiovascular & Hematological Agents in Medicinal Chemistry
Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?
Sean G. Yates, Sabra Smith, William Tharpe, Yu-Min Shen, Ravi Sarode · 2016 · Transfusion and Apheresis Science
Liver transplant recipients with portal vein thrombosis receiving an organ from a high-risk donor are at an increased risk for graft loss due to hepatic artery thrombosis
Jonathan G. Stine, Curtis Kent Argo, Shawn J. Pelletier, Daniel G. Maluf, Patrick Grant Northup · 2016 · Transplant International
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
Nina Haagenrud Schultz, Runar Lundblad, Pål André Holme · 2018 · Journal of Medical Case Reports
Management of Stroke in the Neurocritical Care Unit
Chethan P. Venkatasubba Rao, José I. Suárez · 2018 · CONTINUUM Lifelong Learning in Neurology
Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study
Monami Ando, Yasuya Inden, Yukihiko Yoshida, Akinori Sairaku, Satoshi Yanagisawa, Hirohiko Suzuki, Ryo Watanabe, Masaki Takenaka, Mayuho Maeda, Toyoaki Murohara · 2019 · Heart and Vessels
Lack of significant bleeding despite large acute rivaroxaban overdose confirmed with whole blood concentrations
Daniel Repplinger, Robert S. Hoffman, Lewis S. Nelson, Elizabeth Quaal Hines, MaryAnn Howland, Mark K. Su · 2016 · Clinical Toxicology
Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists
Sean T. Chen, Manesh R. Patel · 2018 · Progress in Cardiovascular Diseases
Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant
Shannon W. Finks, Kelly C. Rogers · 2016 · The American Journal of Medicine
Direct oral anticoagulants (DOACs) and neck of femur fractures: Standardising the perioperative management and time to surgery
Rohi Shah, Nomaan Sheikh, Jitendra Mangwani, N. J. Morgan, Hamidreza Khairandish · 2020 · Journal of Clinical Orthopaedics and Trauma
Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?
Nicolas Gendron, Paul Billoir, Virginie Siguret, Véronique Le Cam‐Duchez, Valérie Proulle, Laurent Macchi, Elodie Boissier, Christine Mouton, Emmanuel de Maistre, Isabelle Gouin‐Thibault et al. · 2024 · Thrombosis Research
Neurologic Emergencies in the Elderly
Lauren M. Nentwich, Benjamin Grimmnitz · 2016 · Emergency Medicine Clinics of North America
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols
Menno Volkert Huisman, John R. Fanikos · 2016 · The American Journal of Emergency Medicine
Betrixaban – the next direct factor Xa inhibitor?
Martin Thoenes, Joan Minguet, Karin Bramlage, Peter Bramlage, Carmen Ferrero · 2016 · Expert Review of Hematology
The X factor: Lack of bleeding after an acute apixaban overdose
Scott M. Leikin, Hina Patel, Katherine L. Welker, Jerrold Blair Leikin · 2016 · The American Journal of Emergency Medicine
Reversal of Systemic Anticoagulants and Antiplatelet Therapeutics
David Dornbos, Shahid Mehdi Nimjee · 2018 · Neurosurgery Clinics of North America
Anticoagulation in CKD and ESRD
Kelvin Leung, Jennifer M. MacRae · 2019 · Journal of Nephrology
Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent
Jason Powell, James Taylor, Scott G. Garland · 2019 · Annals of Pharmacotherapy
Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats
Bartłomiej Kałaska, Joanna Mikłosz, Kamil Kamiński, Justyna Swieton, Aleksandra Jakimczuk, Shin‐ichi Yusa, Dariusz Pawlak, Maria Nowakowska, Krzysztof Szczubiałka, Andrzej Mogielnicki · 2020 · Journal of Pharmacology and Experimental Therapeutics
Outcomes of Rivaroxaban Use in Patients With Sickle Cell Disease
Shubha Bhat, Jin Han · 2016 · Annals of Pharmacotherapy
Indications and Methods of Anticoagulation Reversal
Jeremy L. Holzmacher, Babak Sarani · 2017 · Surgical Clinics of North America
Anesthesia for Cardiac Ablation
Satoru Fujii, Jian Ray Zhou, Achal Kumar Dhir · 2017 · Journal of Cardiothoracic and Vascular Anesthesia
Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin
Thorsten Send, Mattis Bertlich, Fritz Horlbeck, Darius Gabriel Schafigh, Saskia Freytag, Klaus Wolfgang Eichhorn, Ingo Gräff, Friedrich Bootz, Mark Jakob · 2018 · International Forum of Allergy & Rhinology
Management of Non-tumoral Portal Vein Thrombosis in Patients with Cirrhosis
Jonathan G. Stine, Patrick Grant Northup · 2018 · Digestive Diseases and Sciences
Reversal of novel oral anticoagulants
Elsayed Abo‐Salem, Richard Clinton Becker · 2016 · Current Opinion in Pharmacology
Efficacy and safety of the drugs used to reverse direct oral anticoagulants: a systematic review and meta‐analysis
Luís Teodoro da Luz, Mylene Marchand, Bartolomeu Nascimento, Homer C. N. Tien, Avery B. Nathens, Prakesh S. Shah · 2017 · Transfusion
Using engineered 6- O -sulfotransferase to improve the synthesis of anticoagulant heparin
Yi Lin, Yongmei Xu, Andrea M. Kaminski, Xiaobing Chang, Vijayakanth Pagadala, Maurice Horton, Guowei Su, Zhangjie Wang, Genmin Lu, Pamela B. Conley et al. · 2020 · Organic & Biomolecular Chemistry
The conundrum of the complex relationship between acute kidney injury and cardiac arrhythmias
Simonetta Genovesi, Giuseppe Regolisti, Alexandru Burlacu, Adrian Constantin Covic, Christian Combe, Sandip Mitra, Carlo Basile, The EuDial Working Group of ERA, Chiara Bartolucci · 2022 · Nephrology Dialysis Transplantation
Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo
Farahnaz Rayatdoost, Katharina Deventer, Rolf Rossaint, Herbert Schöchl, Oliver Grottke · 2023 · British Journal of Anaesthesia
Anticoagulation Therapy Considerations in Factor VII Deficiency
Eric J. Paulus, Kathy E. Komperda, Gabriel Park, Julie A. Fusco · 2016 · Drug Safety - Case Reports
Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention
Jeffrey Habert · 2016 · International Journal of General Medicine
Management of acute stroke in patients on oral anticoagulants
Jan Christoph Purrucker, Thorsten Steiner · 2016 · Current Opinion in Neurology
Role of agents for reversing the effects of target-specific oral anticoagulants
Tanya R. Riley, Mary L. Gauthier-Lewis, Chelsea K. Sanchez, Janine S. Douglas · 2017 · American Journal of Health-System Pharmacy
Kommentar zu den 2016 Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management von Vorhofflimmern
Lars Eckardt, Thomas Deneke, HC Diener, Gerhard Hindricks, Hans Martin Hoffmeister, Stefan Hans Hohnloser, Paulus F. Kirchhof, Christoph Stellbrink · 2017 · Der Kardiologe
Non-Vitamin K Oral Anticoagulants Associated Bleeding and Its Antidotes
Thorsten Steiner, Martin Köhrmann, Peter Dieter Schellinger, Georgios K. Tsivgoulis · 2018 · Journal of Stroke
Clinical and endoscopic features of severe acute gastrointestinal bleeding in elderly patients treated with direct oral anticoagulants: a multicentre study
David Deutsch, Pauline Romegoux, Christian Boustière, Jean‐Marc Sabaté, Robert Benamouzig, Pierre Albaladejo · 2019 · Therapeutic Advances in Gastroenterology
Pylephlebitis treated with apixaban
Graham R. Hale, Leon Alan Sakkal, Taki Galanis · 2019 · Hospital Practice
Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban
Merav Barzilai, Ilya Kirgner, Arza Steimatzky, Dalit Salzer Gotler, Yulia Belnick, Adi Shacham‐Abulafia, Irit Mazza Avivi, Pia Raanani, Vered Yahalom, Sigal Nakav et al. · 2019 · Acta Haematologica
Anticoagulation in Deep Venous Thrombosis: Current Trends in the Era of Non- Vitamin K Antagonists Oral Anticoagulants
Panteleimon Ε. Papakonstantinou, Costas P. Tsioufis, D. Konstantinidis, Panagιotis Iliakis, Ioannis Leontsinis, Dimitrios M. Tousoulis · 2020 · Current Pharmaceutical Design
Targeting Biological Polyanions in Blood: Strategies toward the Design of Therapeutics
Chanel C. La, Lily E. Takeuchi, Srinivas Abbina, Sreeparna Vappala, Usama Abbasi, Jayachandran N. Kizhakkedathu · 2020 · Biomacromolecules
Direct oral anticoagulants: a guide for daily practice
Pierre Fontana, Helia Robert‐Ebadi, Henri Bounameaux, Françoise Boehlen, Marc Righini · 2016 · Swiss Medical Weekly
The role of new oral anticoagulants in orthopaedics: an update of recent evidence
Dimitrios V. Papadopoulos, Ioannis Kostas‐Agnantis, Ioannis S. Gkiatas, Andreas G. Tsantes, Panagiota Ziara, Anastasios V. Korompilias · 2017 · European Journal of Orthopaedic Surgery & Traumatology
The Reversal of Bleeding Caused by New Oral Anticoagulants (NOACs): A Systematic Review and Meta-Analysis
Sariya Udayachalerm, Sasivimol Rattanasiri, Teeranan Angkananard, John Attia, Nakarin Sansanayudh, Ammarin Thakkinstian · 2018 · Clinical and Applied Thrombosis/Hemostasis
Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects
Emmanuel J. Favaloro, Grace Gilmore, Roslyn A. Bonar, Elysse Dean, Sandya Arunachalam, Soma Mohammed, Ross Ian Baker · 2020 · Haemophilia
Photodegradation of novel oral anticoagulants under sunlight irradiation in aqueous matrices
Montaha Yassine, Laura Fuster, Marie‐Hélène Devier, E. Geneste, Patrick R. Pardon, Axelle Grélard, Érick J. Dufourc, Mohamad Al Iskandarani, Sélim Aı̈t-Aı̈ssa, Jeanne Garric et al. · 2017 · Chemosphere
Reversal Agents for Direct Oral Anticoagulants
Kelly C. Rogers, Melanie P. Shelton, Shannon W. Finks · 2016 · Cardiology in Review
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols
Menno Volkert Huisman, John R. Fanikos · 2016 · The American Journal of Medicine
Thrombosis, Hypercoagulable States, and Anticoagulants
Marie A. Hollenhorst, Elisabeth M. Battinelli · 2016 · Primary Care Clinics in Office Practice
Antidotes for the direct oral anticoagulants: What news?
Silvia Galliazzo, Marco Paolo Donadini, Walter Ageno · 2018 · Thrombosis Research
Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
Young‐A Heo · 2018 · Drugs & Therapy Perspectives
Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
Mette Søgaard, Peter Brønnum Nielsen, Flemming Skjøth, Jette Nordstrøm Kjældgaard, Torben Bjerregaard Larsen · 2019 · Cancer Medicine
Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization
Tigran Khachatryan, Christopher Hauschild, Jason Hoff, Tahmeed A. Contractor, Arthur Khachatryan, Huyentran N Tran, Bert Matsuo, Alan K. Jacobson, Anthony A. Hilliard · 2019 · American Journal of Cardiovascular Drugs
Transient or extended reversal of apixaban anticoagulation by andexanet alfa is equally effective in a porcine polytrauma model
Oliver Grottke, Till A. Braunschweig, Rolf Rossaint, Necib Akman, Janet M. Leeds, Pamela B. Conley, Markus Honickel · 2019 · British Journal of Anaesthesia
Perioperative Management of Patients Receiving New Anticoagulants
Massimo Lamperti, Andrey Khozenko, Arun H. S. Kumar · 2019 · Current Pharmaceutical Design
Present Knowledge on Direct Oral Anticoagulant and Novel Oral Anti Coagulants and Their Specific Antidotes: A Comprehensive Review Article
Suman Biswas, Yasemin Bahar, Abdul Rasheed Bahar, Israel Safiriyu, Sheetal Vasundara Mathai, Adrija Hajra, Rahul Gupta, Wilbert S. Aronow · 2022 · Current Problems in Cardiology
Novel Oral Anticoagulants for Venous Thromboembolism with Special Emphasis on Risk of Hemorrhagic Complications and Reversal Agents
Zaheer Ahmed, Seemeen Hassan, Gary A. Salzman · 2016 · Current Drug Therapy
Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
Blake Charlton, Gboyega Adeboyeje, John J. Barron, Deborah G. Grady, Jaekyu Shin, Rita F. Redberg · 2018 · PLoS ONE
Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies
Mark Schreuder, Pieter H. Reitsma, Mettine H.A. Bos · 2020 · Seminars in Thrombosis and Hemostasis
Efficacy and Safety of Andexanet Alfa Versus Four Factor Prothrombin Complex Concentrate for Emergent Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage: A Systematic Review and Meta-Analysis
Khalid Sarhan, Rashad G. Mohamed, Reem Reda Elmahdi, Youstina Mohsen, Asmaa Elsayed, Dania Mosaad Zayed, Menna A. Elkholi, Nagat Gabr, Enjy M. El-Bialy, Ibrahim Serag · 2024 · Neurocritical Care
Overview of direct oral anticoagulant therapy reversal
Michael P. Gulseth · 2016 · American Journal of Health-System Pharmacy
Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues
Hans‐Christoph Diener, Christoph Kleinschnitz · 2016 · Journal of Stroke
The anticoagulation choices of internal medicine residents for stroke prevention in non-valvular atrial fibrillation
Nathaniel Moulson, William F. McIntyre, Zardasht Oqab, Payam Yazdan-Ashoori, Kieran L. Quinn, Erik M. van Oosten, Wilma M. Hopman, Adrian M Baranchuk · 2016 · Postgraduate Medical Journal
Reversal agents for direct oral anticoagulants: A focused review
Boris Arbit, Marin Nishimura, Jonathan Chong Hsu · 2016 · International Journal of Cardiology
Proposal for the Rapid Reversal of Coagulopathy in Patients with Nonoperative Head Injuries on Anticoagulants and/or Antiplatelet Agents: A Case Study and Literature Review
Victoria L. Watson, Nundia Louis, Brittany V. Seminara, Jan Paul Muizelaar, Anthony M. Alberico · 2017 · Neurosurgery
Novel Anticoagulant Agents in the Perioperative Setting
Allyson Lemay, Alan D. Kaye, Richard D. Urman · 2017 · Anesthesiology Clinics
Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent
Lauren K. Ely, Marco Lolicato, Tovo David, Kate L. Lowe, Yun Cheol Kim, Dharmaraj Samuel, Paul H. Bessette, J. Luz Tovar García, Thomas Mikita, Daniel L. Minor et al. · 2018 · Structure
Bleeding and thrombotic outcomes associated with postoperative use of direct oral anticoagulants after open peripheral artery bypass procedures
Andrea T. Obi, Jonathan R. Thompson, Robert J. Beaulieu, Danielle C. Sutzko, Nicholas H. Osborne, Jeremy Albright, Katherine Ann Gallagher, Peter K. Henke · 2020 · Journal of Vascular Surgery
Prevention and Treatment of Bleeding with Direct Oral Anticoagulants
R. Monroe Crawley, Rachel Lynn Anderson · 2020 · Drugs
The incidence of thrombotic events with idarucizumab and andexanet alfa: A systematic review and meta-analysis
André Oliveira Rodrigues, Cláudio David, Joaquim José Ferreira, Fausto José Pinto, João N. Costa, Daniel Caldeira · 2020 · Thrombosis Research